Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dezembro 2023 - 7:00PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced making Inducement Grants Under NASDAQ
Listing Rule 5635(c)(4) in connection with the employment and
appointment of Harold D. Tamayo as Vice President of Finance and
Investor Relations. Mr. Tamayo will report to Peter J. Mariani,
Executive Vice President and Chief Financial Officer, and will be
responsible for Financial Planning and Analysis and Investor
Relations.
Mr. Tamayo has over 20 years of experience in
healthcare and life sciences including as a division CFO and in
leadership roles in Investor Relations and Corporate FP&A in
companies such as McKesson, Merck, Novartis, and CVS Health. Most
recently he served as Interim CFO of Neighborhood LTC Pharmacy, a
technology healthcare management and pharmacy company in Lincoln,
NE. Prior to this he served as SVP Corporate Finance, M&A,
Investor Relations for McKesson, a diversified healthcare company.
Mr. Tamayo earned his Bachelor of Science in Electrical Engineering
from Florida International University, followed by dual master’s
degrees in business administration and industrial engineering from
the University of Miami.
In connection with the commencement of his
employment on November 27, 2023, and as a material inducement of
employment, Mr. Tamayo was awarded an equity grant on December 1,
2023, consisting of (i) non-qualified stock options to purchase
65,800 shares of the Company’s common stock and (ii) non-qualified
restricted stock units (“RSUs”) representing 37,500 shares of the
Company’s common stock. The stock options have an exercise price of
$6.88 per share, a 10-year term, and will vest over a four-year
period, with 50% vesting after the second year and 12.5% of the
total shares granted vesting every six months thereafter for the
next two years. The RSUs are subject to vesting over 4 years, with
50% vesting after the second year and 25% of the total shares
granted vesting every year thereafter for the next two years.
About Axogen
Axogen (AXGN) is the leading Company focused
specifically on the science, development, and commercialization of
technologies for peripheral nerve regeneration and repair. Axogen
employees are passionate about helping to restore peripheral nerve
function and quality of life to patients with physical damage or
transection to peripheral nerves by providing innovative,
clinically proven, and economically effective repair solutions for
surgeons and health care providers. Peripheral nerves provide the
pathways for both motor and sensory signals throughout the body.
Every day, people suffer traumatic injuries or undergo surgical
procedures that impact the function of their peripheral nerves.
Physical damage to a peripheral nerve, or the inability to properly
reconnect peripheral nerves, can result in the loss of muscle or
organ function, the loss of sensory feeling, or the initiation of
pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products that are used across
two primary application categories: scheduled, non-trauma
procedures and emergent trauma procedures. Scheduled procedures are
generally characterized as those where a patient is seeking relief
from conditions caused by a nerve defect or surgical procedure.
These procedures include providing sensation for women seeking
breast reconstruction following a mastectomy, nerve reconstruction
following the surgical removal of painful neuromas, oral and
maxillofacial procedures, and nerve decompression. Emergent
procedures are generally characterized as procedures resulting from
injuries that initially present in an ER. These procedures are
typically referred to and completed by a specialist either
immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa ECM coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; Axoguard
HA+ Nerve Protector™, a porcine submucosa ECM base layer coated
with a proprietary hyaluronate-alginate gel, a next-generation
technology designed to provide short- and long-term protection for
peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine
submucosa ECM product used to protect a peripheral nerve end and
separate the nerve from the surrounding environment to reduce the
development of symptomatic or painful neuroma. The Axogen portfolio
of products is available in the United States, Canada, Germany, the
United Kingdom, Spain, South Korea, and several other
countries.
Contact:Axogen, Inc.Harold D. Tamayo,
VP of Finance and Investor
Relationshtamayo@axogeninc.com
Axogen (NASDAQ:AXGN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Axogen (NASDAQ:AXGN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024